| 
            Only notified under the "contained use" procedure. Dossier submitted on 02/12/2019.           | 
                  
            A multicentre, open-label, single ascending dose, dose-ranging, phase I/Iia study to evaluate the safety and tolerability of an autologous antigen-specific chimeric antigen receptor T regulatory cell therapy (TX200-TR101) in living donor renal transplant            | 
                  
                  
            Humans           | 
                  
            chimeric antigen receptor specific to the donor HLA A*2           | 
              
          
                  | 
            B/BE/08/BVW1           | 
                  
            MI-CP178: Study of a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to < 24 Month-Old Children and in 2 Month-Old Infants           | 
                  
                  
            Humans           | 
                  
            Genes of the human Parainfluenza virus fusion (F) and hemagglutinin-neuraminidase (HN) proteins; gene of the human Respiratory syncitial virus fusion protein (RSV F).           | 
              
          
                  | 
            Only notified under the "contained use" procedure. Dossier submitted on 05/07/2005.           | 
                  
            A multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy of Biobypass (ADGVVEGF121.10NH) delivered by NOGATM-guided/MYOSTARTM catheter in "no option" patients with class II-IV stable angina           | 
                  
                  
            Humans           | 
                  
            human VEGF121           |